LIVE WEBINAR: Wednesday, October 15, 2025 | 5:00 PM – 6:00 PM Eastern Time (ET)
Practical Perspectives: Experts Review Actual Cases of Patients with Endometrial Cancer
A CME/MOC-Accredited Live Webinar
Event Details
Join us on Wednesday, October 15th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET
Kathleen N Moore, MD, MS
Deputy Director
Virginia Kerley Cade Chair in Developmental Therapeutics
Co-Director, Cancer Therapeutics Program
Stephenson Cancer Center at the University
of Oklahoma HSC
Associate Director, GOG Partners
Board of Directors, GOG Foundation
Board of Directors, ASCO
Oklahoma City, Oklahoma
Matthew A Powell, MD
Ira C and Judith Gall Professor
Division of Gynecologic Oncology
Chair, Uterine Corpus Committee
National Cancer Institute-Sponsored NRG Oncology
Washington University School of Medicine
St Louis, Missouri
Neil Love, MD
Research To Practice
Miami, Florida
Agenda
Wednesday, October 15, 2025
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar
Topics to Be Discussed
- Selection and sequencing of therapy for patients with microsatellite instability-high/mismatch repair-deficient and microsatellite-stable/mismatch repair-proficient metastatic endometrial cancer
- Combining immunotherapy and chemotherapy for patients with newly diagnosed advanced endometrial cancer
- Utility of maintenance therapy with PARP inhibitors as monotherapy and in combination with immunotherapy for patients with advanced endometrial cancer
- Relevance of biomarker testing in the optimization of treatment for patients with endometrial cancer
- Management of adverse events associated with treatment
- Other novel treatment strategies for advanced endometrial cancer
CE Information
Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the diagnosis and treatment of endometrial cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
- Evaluate the importance of microsatellite instability (MSI) and mismatch repair (MMR) deficiency assessment for patients with endometrial cancer (EC), and apply current testing practices to optimally identify individuals with these genetic abnormalities.
- Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent EC, and consider the current role of this novel strategy for patients with MSI-high/MMR-deficient and microsatellite-stable/MMR-proficient disease.
- Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and select patients with metastatic EC for treatment with this novel approach.
- Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC.
- Evaluate published clinical research documenting the efficacy of HER2-targeted agents and regimens for HER2-overexpressing EC, and consider the role of various approaches in patient care.
- Recognize adverse events associated with available and investigational therapies for EC to educate patients and manage complications.
- Describe the scientific justification for, published research data with and current studies of novel agents and strategies for EC, and effectively prioritize clinical trial opportunities for eligible patients.
CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from GSK and Merck.